https://www.bioworld.com/rss en-us Estrigenix Therapeutics Inc. has closed the first $2 million tranche of a seed financing to move its selective estrogen receptor-β (ERβ) platform through translational preclinical development. http://www.bioworld.com/articles/732823 Wed, 22 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732823-estrigenix-therapeutics-raises-financing-to-advance-er-platform Dollar sign in lightbulb Rinascera Therapeutics Inc. has secured enough initial funding to acquire two drugs for rare genetic skin diseases, despite stalled development with their previous owners. The company, whose name comes from the Latin root renasci – to be born again, was incubated by Olive Tree Capital, which led the seed round with participation from Civilization Ventures and Toba Capital. http://www.bioworld.com/articles/732735 Mon, 20 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732735-rinascera-launches-with-two-rare-genetic-skin-disease-therapies Skin exam Lyora Therapeutics Inc. has launched with seed funding and a focus on genetic medicines targeting the root cause of inherited retinal diseases. The company has acquired advanced preclinical assets, which it plans to optimize and advance to be delivered locally and remain durable for life. http://www.bioworld.com/articles/732645 Wed, 15 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732645-lyora-therapeutics-launches-with-focus-on-retinal-diseases Hand holding lightbulb Artan Biotechnologies LLC has closed a $1 million seed round to support progression of the company’s proprietary mutation-specific codon suppression platform toward first-in-human development. http://www.bioworld.com/articles/732358 Thu, 02 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732358-artan-closes-seed-round-to-support-trna-platform Coins and seedling Artan Biotechnologies LLC has completed a $200,000 seed raise to fund preclinical advancement of the company’s proprietary engineered suppressor platform, which targets nonsense mutations. http://www.bioworld.com/articles/731677 Fri, 05 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731677-seed-funding-at-artan-bio-supports-work-on-aging Woman and molecular overlay Protuoso Biosciences has announced the close of an oversubscribed $9.5 million seed financing round, the proceeds of which will be used to advance its multifunctional protein engineering platform and broad pipeline across cardiometabolic, oncology and autoimmune diseases. http://www.bioworld.com/articles/731477 Thu, 28 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731477-protuoso-biosciences-building-multifunctional-protein-engineering-platform Drug R&D concept image. Reprogram Biosciences Inc., a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, has announced the close of its seed financing, bringing the total capital raised to $6 million since the company’s founding in 2025. http://www.bioworld.com/articles/731476 Thu, 28 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731476-reprogram-biosciences-secures-financing-for-solid-tumor-mrna-work Wireframe hands, coins Re-Aim Therapeutics Ltd. has launched with £7 million (US$9.4 million) in seed investment backing and a focus on developing functional cures for T-cell-mediated autoimmune diseases. http://www.bioworld.com/articles/731176 Wed, 20 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731176-re-aim-therapeutics-launches-with-focus-on-autoimmune-diseases Syringe, vial with pound currency symbol Scarlet Therapeutics Ltd. has demonstrated its manufactured red blood cells (RBCs) act in the same way as their natural counterparts in vivo, opening the way for the cells to be used as drug delivery vehicles and raising the possibility they could replace conventional blood transfusions. To build on this, Scarlet has closed a $4 million seed round to work on the first clinical application, in which RBCs loaded with therapeutic proteins will be used to treat rare metabolic diseases. http://www.bioworld.com/articles/730981 Fri, 08 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730981-scarlet-raises-4m-to-take-manufactured-red-blood-cells-into-clinic Red blood cells Parcelbio has raised $13 million in seed financing to continue its development of a new class of potent and durable mRNA medicines. The financing will support development of Parcelbio’s proprietary APEXm (Amplified and Prolonged EXpression mRNA) platform and advance its pipeline, including its lead in vivo CAR T program for autoimmune disease. http://www.bioworld.com/articles/730949 Fri, 08 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730949-seed-financing-at-parcelbio-to-advance-mrna-medicines Illustration of messenger RNA Signadori Bio SAS has successfully completed its seed extension financing round, bringing to €11.1 million (US$13 million) the total raised to support its development of a next-generation, off-the-shelf, in vivo-engineered, monocyte immunotherapy platform to treat solid tumors. http://www.bioworld.com/articles/730905 Wed, 06 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730905-funding-at-signadori-bio-to-advance-monocyte-immunotherapies Green money bag tiles stacked on tile with microscope icon Tacalyx GmbH has selected its first clinical candidate, TCX-201, and secured €11 million (US$12.8 million) in a first closing of its seed extension round to support the program’s progression through preclinical development. TCX-201 is an antibody-drug conjugate (ADC) against an undisclosed tumor-associated carbohydrate antigen (TACA). http://www.bioworld.com/articles/730791 Thu, 30 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730791-tacalyx-supports-tcx-201-with-seed-extension-financing Ferrosa Therapeutics AG has announced a $3.5 million seed financing to support the development of a first-in-class bispecific antibody (FRS-101) to treat anemia of inflammation across chronic kidney disease, autoimmune disease and oncology indications. http://www.bioworld.com/articles/730634 Fri, 24 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730634-seed-funding-at-ferrosa-therapeutics Coins and seedling Tippingpoint Biosciences Inc. has closed an oversubscribed $4.5 million seed financing. The company, spun out of a lab at University of California, San Francisco (UCSF), is advancing its novel drug discovery platform designed to identify first-in-class drugs to treat diseases related to dysfunctional DNA packaging (chromatin). http://www.bioworld.com/articles/730061 Wed, 01 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730061-tippingpoint-raises-seed-financing-to-target-epigenetic-protein-interfaces Chromatin compaction Newco Idel Therapeutics GmbH has closed a €9 million (US$10.4 million) seed round to advance the development of a technology for delivery of cytotoxic drugs directly into the cytosol of tumor cells. http://www.bioworld.com/articles/729904 Thu, 26 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729904-idel-raises-104m-for-intracellular-pan-cancer-drug-delivery-tech Cancer cells under magnifying glass Rybodyn Inc. has announced the initial close of a $10 million seed financing to support its work decoding the dark proteome using an AI-powered novel sequencing and discovery platform. The financing will accelerate the company’s transition from foundational discovery into scaled platform execution and progress early-stage programs into IND-enabling studies. http://www.bioworld.com/articles/729878 Wed, 25 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729878-rybodyn-raises-funding-to-decode-the-dark-proteome Art concept for medical research Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage financings in China biotech history. http://www.bioworld.com/articles/729898 Tue, 24 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729898-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers Blue-gray dollar sign Laigo Bio BV has extended its seed round to €17 million (US$19.8 million), after making progress with translating its novel E3 ubiquitin ligase targeted protein degradation technology toward the clinic. http://www.bioworld.com/articles/729812 Mon, 23 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729812-laigo-extends-seed-round-as-targeted-protein-degradation-field-gathers-pace White Euro symbol on blue background Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage financings in China biotech history. http://www.bioworld.com/articles/729788 Thu, 19 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729788-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers Blue-gray dollar sign Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage financings in China biotech history. http://www.bioworld.com/articles/729560 Wed, 18 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729560-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers Blue-gray dollar sign Enodia Therapeutics Inc. was spun out of The Institut Pasteur by Argobio Studio based on the work of Caroline Demangel, co-founder of Enodia and head of the immunobiology and therapy unit at The Institut Pasteur. Demangel’s lab discovered the mechanism of action of mycolactone, a natural Sec61 inhibitor that causes Buruli ulcers. http://www.bioworld.com/articles/729706 Tue, 17 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729706-enodia-jumps-ahead-in-sec61-targeting-adds-kezars-program Tinted Euro symbol Enodia Therapeutics Inc. was spun out of The Institut Pasteur by Argobio Studio based on the work of Caroline Demangel, co-founder of Enodia and head of the immunobiology and therapy unit at The Institut Pasteur. Demangel’s lab discovered the mechanism of action of mycolactone, a natural Sec61 inhibitor that causes Buruli ulcers. http://www.bioworld.com/articles/729529 Mon, 16 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729529-enodia-jumps-ahead-in-sec61-targeting-adds-kezars-program Tinted Euro symbol Gelmedix Inc. has completed a $13 million seed financing to support progression of the company’s lead program, GMX-101, a retinal pigment epithelial (RPE) cell therapy to treat late-stage geographic atrophy. http://www.bioworld.com/articles/728920 Wed, 18 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728920-financing-at-gelmedix-supports-gmx-101-for-geographic-atrophy Dollar sign droplet above test tube Newco ALTx Therapeutics Ltd. has launched with a £12.55 million (US$17.1 million) seed round to develop inhibitors of the alternative lengthening of telomeres (ALT) pathway, by which 10% to 15% of cancers become immortal. http://www.bioworld.com/articles/728760 Fri, 06 Feb 2026 09:00:00 -0500 https://www.bioworld.com/articles/728760-altx-formed-to-drug-pathway-by-which-cancer-cells-become-immortal Chromosome with shortened telomeres Newco ALTx Therapeutics Ltd. has launched with a £12.55 million (US$17.1 million) seed round to develop inhibitors of the alternative lengthening of telomeres (ALT) pathway, by which 10% to 15% of cancers become immortal. http://www.bioworld.com/articles/728645 Thu, 05 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728645-altx-formed-to-drug-pathway-by-which-cancer-cells-become-immortal Chromosome with shortened telomeres Enodia Therapeutics SAS has raised €20.7 million ($25 million) in seed financing to advance its work developing novel small-molecule therapies for targeted protein degradation at the point of synthesis. http://www.bioworld.com/articles/727914 Mon, 12 Jan 2026 08:00:00 -0500 https://www.bioworld.com/articles/727914-seed-funding-at-enodia-for-targeted-protein-degradation-platform Shanx Medtech BV raised €15 million (US$17.5 million) in a seed funding round for its in vitro diagnostic platform for ultra-rapid antimicrobial susceptibility testing. The financing came from a range of sources including equity, grants and a loan, and will be used to accelerate the development, clinical validation, regulatory approval, and commercial launch of the diagnostic platform. http://www.bioworld.com/articles/727586 Wed, 07 Jan 2026 11:00:00 -0500 https://www.bioworld.com/articles/727586-shanx-secures-15m-to-accelerate-rapid-antimicrobial-testing Shanx Medtech IVD Shanx Medtech in vitro diagnostic platform for ultra-rapid antimicrobial susceptibility testing. Credit: Shanx Medtech BV Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by E3 ubiquitin ligases. http://www.bioworld.com/articles/726926 Fri, 05 Dec 2025 09:00:00 -0500 https://www.bioworld.com/articles/726926-laigo-raises-115m-seed-money-for-targeted-protein-degradation 3D Euro symbol Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by E3 ubiquitin ligases. http://www.bioworld.com/articles/726817 Thu, 04 Dec 2025 12:00:00 -0500 https://www.bioworld.com/articles/726817-laigo-raises-115m-seed-money-for-targeted-protein-degradation 3D Euro symbol Junevity Inc. has raised $10 million in new funding, bringing its seed financing to a total of $20 million. The new funding will enable Junevity to advance JUN-01, its lead siRNA program for type 2 diabetes and obesity, through IND-enabling and initial clinical studies. http://www.bioworld.com/articles/726804 Thu, 04 Dec 2025 08:00:00 -0500 https://www.bioworld.com/articles/726804-junevity-raises-funds-to-advance-sirna-metabolism-program Illustration of glucose molecules in a bloodstream